文献速递淋巴瘤

单药伊布替尼治疗复发或难治性滤泡性淋巴瘤:一项2期联盟试验

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
PubMed 文献 · Blood · 2017-10-26

该2期试验评估单药伊布替尼560 mg/d治疗40例复发滤泡性淋巴瘤,总缓解率37.5%、完全缓解率12.5%、中位无进展生存期14个月、2年无进展生存率20.4%;利妥昔单抗敏感者缓解率52.6%高于耐药者16.7%(P=0.04),CARD11突变患者均无缓解(P=0.002)。

要点

  • 单药伊布替尼在复发滤泡性淋巴瘤中总缓解率37.5%,完全缓解率12.5%。
  • 利妥昔单抗敏感者缓解率52.6%,高于耐药者的16.7%(P=0.04)。
  • CARD11突变见于16%(5/31)患者,且仅野生型患者出现缓解(P=0.002)。

核心结论

  • 伊布替尼耐受性良好,在复发滤泡性淋巴瘤中活性有限。
  • 基于利妥昔单抗敏感疾病中缓解率更高,可能有必要在更早线治疗中评估BTK抑制剂。
  • CARD11等体细胞突变可能影响伊布替尼的缓解,可能为临床决策提供信息,并应在更大数据集中评估。

研究设计与样本

  • 2期联盟试验,40例复发滤泡性淋巴瘤患者接受伊布替尼560 mg/d直至进展或不耐受。
  • 主要终点为总缓解率;探索性分析包括31例治疗前活检中癌症基因 panel 下一代测序所识别的复发突变与结局的相关性,以及20例患者早期中期正电子发射断层扫描/计算机断层扫描结果。
  • 试验注册号为NCT01849263。

主要发现

  • 总缓解率为37.5%,完全缓解率为12.5%,中位无进展生存期为14个月,2年无进展生存率为20.4%。
  • 利妥昔单抗敏感患者的缓解率为52.6%,高于利妥昔单抗耐药患者的16.7%(P=0.04)。
  • CARD11突变见于16%(5/31)患者,且仅野生型患者出现缓解(P=0.002)。
  • 第1周期第8天最大标准化摄取值与缓解和无进展生存期相关。
  • 伊布替尼耐受性良好,毒性特征与已获批适应症相似。

局限性

  • 作者指出,基于利妥昔单抗敏感疾病中缓解率更高,可能有必要在更早线治疗中评估BTK抑制剂。
  • 作者指出,CARD11等体细胞突变应在更大数据集中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase 1 study. We report the results of a phase 2 trial evaluating ibrutinib in recurrent FL. Forty patients with recurrent FL were treated with ibrutinib 560 mg/d until progression or intolerance. The primary end point was overall response rate (ORR). Exploratory analyses included correlations of outcome with recurrent mutations identified in a cancer gene panel that used next-generation sequencing in pretreatment biopsies from 31 patients and results of early interim positron emission tomography/computed tomography scans in 20 patients. ORR was 37.5% with a complete response rate of 12.5%, median progression-free survival (PFS) of 14 months, and 2-year PFS of 20.4%. Response rates were significantly higher among patients whose disease was sensitive to rituximab (52.6%) compared with those who were rituximab refractory (16.7%) (P = .04). CARD11 mutations were present in 16% of patients (5 of 31) and predicted resistance to ibrutinib with only wild-type patients responding (P = .002). Maximum standardized uptake value at cycle 1 day 8 correlated with response and PFS. Ibrutinib was well-tolerated with a toxicity profile similar to labeled indications. Ibrutinib is a well-tolerated treatment with modest activity in relapsed FL. Evaluation of BTK inhibitors in earlier lines of therapy may be warranted on the basis of improved response rates in rituximab-sensitive disease. Somatic mutations such as CARD11 may have an impact on response to ibrutinib, may inform clinical decisions, and should be evaluated in larger data sets. This trial was registered at www.clinicaltrials.gov as #NCT01849263.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2017. PMID: 29074501. doi:10.1182/blood-2017-09-804641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。